medigraphic.com

2018, Number 1

<< Back Next >>

Rev Fac Med UNAM 2018; 61 (1)

Devic’s disease. A case report and literature review

Medina RR, Sánchez JA, Bertado CB, Martínez CCE, Martínez MM

Language: Spanish
References: 21
Page: 26-32
PDF size: 928.76 Kb.


ABSTRACT

Optic neuromyelitis or Devic’s disease is a rare inflammatory disease of the central nervous system (CNS) that predominantly affects the optic nerve and spinal cord. The mechanism of the disease is given by the production of IgG antibodies whose main target is the acuaporine channel 4 (AQP4) that trigger an inflammatory and demyelinating process in the aforementioned structures. We present the case of a patient who developed chronic and fluctuating sensitive episodes with visual impairment, without improvement after conventional treatment. During the diagnostic approach we found demyelinating lesions and positive AQP4-antibodies, this lead to a diagnosis of optic neuromyelitis. A positive response was obtained to the therapy with monoclonal antibodies.


REFERENCES

  1. Pittock SJ. Neuromyelitis optica: a new perspective. Semin Neurol. 2008;28:95-104.

  2. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-7.

  3. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoanti-body marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106-12.

  4. Flanagan EP, Weinshenker BG. Neuromyelitis optica spectrum disorders. Curr Neurol Neurosci Rep. 2014;14:483.

  5. Evangelopoulos ME, Andreadou E, Koutsis G, Koutoulidis V, Anagnostouli M, Katsika P, et al. Treatment of Neuromyelitis optica and Neuromyelitis Optica Spectrm Disorders with Rituximab using a maintenance treatment régimen and close CD19 B cells monitoring. A six years follow-up. Journal of the Neurological Sciences. 2016;372:92-6.

  6. Etemadifar N, Nasr Z, Khalili B, Taherioun M, Vosoughi R. Epidemiology of Neuromyelitis Optica in the World: A Systematic Review and Meta-Analysis. Mult Scler Int. 2015:174720.

  7. Wingerchuk DM. Neuromyelitis optica: effect of gender. J Neurol Sci. 2009;286(1-2):18-23.

  8. Tengsirikomol T, Siritho S, Parayoonwiwat N. How long does it take to diagnose patients with neuromyelitis óptica (NMO) using the 2006 diagnostic criteria? Multiple Sclerosis and Related Disorders. 2016;9:14-6.

  9. Quek AM, McKeon A, Lennon VA, Mandrekar JN, Iorio R, Jiao Y, et al. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol. 2012;69(8):1039-43.

  10. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(6):1834-49.

  11. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176-80.

  12. Flores J, Kurtzke J, Alatriste V, et al. Characteristics of Devic’s disease (neuromyelitis optica) in Mexico. J Neurol. 2008;255(5):710-5.

  13. Papadopoulos MC, Verkman AS. Aquaporin4 and neuromyelitis óptica. Lancet Neurol. 2012;11(6):535-44.

  14. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-15.

  15. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89.

  16. Pandit L. Neuromyelitis optica spectrum disorders: An update. Ann Indian Acad Neurol 2015;18, Suppl S1:11-5.

  17. Jennings W, Vissoci E, Kallaur A, et al. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review. J Neurol Sci. 2015 Aug 15;355(1-2):7-17.

  18. Chiquete E, Navarro-Bonnet J, Ayala-Armas R, Gutiérrez- Gutiérrez N, Solórzano-Meléndez A, Rodriguez-Tapia D, et al. Neuromielitis óptica: actualización clínica. Rev Neurol. 2010;51:289-94.

  19. Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014;20(4):501-4.

  20. Kim SH, Hyun JW, Joung A, Park EY, Joo J, Kim HJ. Predictors of response to first-line immunosuppressive therapy in neuromyelitis óptica spectrum disorders. Multiple Sclerosis Journal. 2017;23(14):1902-8.

  21. Crout T, Parks L, Majithia V. Neuromyelitis Optica (Devic’s Syndrome): an Appraisal. Curr Rheumatol Rep. 2016;8:54.




2020     |     www.medigraphic.com